Engineers specifying 3D-printed medical devices must converge on three constraints simultaneously: ISO/ASTM process class, ISO 10993 biocompatibility testing, and FDA 21 CFR 820 quality-system documentation, with titanium alloys (Ti-6Al-4V), 316L stainless steel, PEEK, PPSU, and photopolymer resins forming the qualified material palette [S1][S2][S3][S4].
Material cost and lead-time vary sharply by category: medical-grade polymers such as PEEK and PPSU carry certification premiums over industrial grades, while titanium powder for laser powder bed fusion (LPBF) remains the dominant metal for load-bearing implants because of its strength-to-density ratio and well-documented osseointegration history [S4][S5][S9].
Process-to-material compatibility under ISO/ASTM 52900
Salmi (2021) categorizes medical additive manufacturing across seven ISO/ASTM process classes, with powder bed fusion (PBF), material extrusion, and VAT photopolymerization covering the widest span of medical applications including implants, instruments, and biomanufacturing [S2]. Binder jetting is excluded for tools and instruments because of residual binder concerns, and directed energy deposition is used almost exclusively for implants [S2].
Common material pairings follow directly from process physics: Ti-6Al-4V and Co-Cr alloys with PBF (selective laser melting, electron beam melting), 316L stainless steel with PBF or binder jetting, PEEK and PPSU with material extrusion (FDM/FFF), and photopolymer resins (typically acrylate or epoxy-based) with VAT photopolymerization (SLA, DLP) [S2][S5][S6]. Mamo (2023) confirms titanium, Co-Cr, 316L, aluminum, gold, and platinum as the recurrent metal palette, with calcium phosphate powders appearing in bone-scaffold work [S5].
Biocompatibility and regulatory gates
ISO 10993 is the international standard for biological evaluation of medical devices, and FDA submissions routinely reference it alongside USP Class VI for plastics [S4]. The Fictiv 2026 selection guide states explicitly that biocompatibility testing depth scales with contact duration, tissue type, implantability, and blood or fluid exposure [S4].
For additively manufactured devices, the FDA's 2017 guidance "Technical Considerations for Additively Manufactured Medical Devices" layers four extra requirements on top of standard 510(k), PMA, and IDE pathways under 21 CFR 820: machine calibration, process validation, post-processing control, and material traceability [S3]. The same guidance requires validation of any reprocessed powder, because heat, oxygen, humidity, and UV exposure can shift particle size distribution, sphericity, chemistry, and flowability between build cycles [S3].
Polymer vs metal vs ceramic: a decision-criteria comparison
Medical-grade thermoplastics dominate non-implant medical devices: ABS, acrylic, PLA, nylon, polycarbonate, and polyethylene are the most commonly cited high-performance grades, with PEEK and PPSU specified where repeated sterilization or higher mechanical load is required [S6]. Polymers win on cost-per-part, design complexity, and rapid iteration, but lose on modulus, fatigue endurance under cyclic load, and long-term imaging artifact control [S4][S6].
Metals win on strength, fatigue life, and established implant history: titanium and its alloys for orthopedic and craniofacial implants, Co-Cr for dental and joint replacements, 316L for surgical instruments and some non-load-bearing implants [S4][S5][S9]. Ceramics and calcium-phosphate bio-inks remain a narrower but growing niche for bone scaffolds and dental applications, and are processed predominantly via VAT photopolymerization for patient-specific geometry [S5][S9].
Where AM material selection is appropriate, and where it is not
AM material selection is appropriate for patient-specific implants, surgical guides, anatomic models, complex lattice orthopedic structures, low-volume custom prosthetics, and dental frameworks where traditional tooling cost would dominate unit economics [S2][S3][S5][S7]. Acrotec (2025) frames this as a metal-versus-polymer decision driven by strength, flexibility, sterilization route, and contact duration [S8].
AM material selection is not appropriate for high-volume disposables where injection molding cost-per-part is one to two orders of magnitude lower, nor for applications without a defensible digital workflow from imaging through validated print parameters [S2][S3]. For high-throughput production, Salmi (2021) notes AM is rarely cheaper than conventional manufacturing when the geometry is designed for mass production and only direct manufacturing cost is compared [S2].
Validation, post-processing, and powder reuse
Particle size distribution, sphericity, chemical purity, and powder flowability are the four material-control parameters Acrotec and Test Labs UK cite as gating for repeatable AM builds, and each must be qualified per lot [S3][S8]. The FDA mandates that any reused powder must be shown not to interfere with structural properties, mechanical behavior, or biocompatibility of the final device, with validation evidence documented in the design history file [S3].
Post-processing controls (support removal, stress relief, hot isostatic pressing for critical Ti-6Al-4V implants, surface finishing, sterilization validation) are part of the AM material specification, not an afterthought, and they directly influence the ISO 10993 test plan because surface chemistry and roughness change biological response [S3][S4]. For metal AM, the link between additive manufacturing material selection and the overall advanced material qualification chain is decisive: a change in powder supplier or atomization batch can invalidate prior test data.
Sourcing, standards, and trackable next signals
Material selection should be cross-referenced against ASTM F2924 (Ti-6Al-4V PBF), ASTM F3091 (316L PBF), ISO 17296-2 to -4 (process fundamentals, general principles, data formats), ISO 10993 (biological evaluation), and ISO/ASTM 52900 (process taxonomy) rather than treated as a free-form engineering choice [S1][S2][S3][S4]. Engineers should also track FDA listings of cleared AM devices and any future revisions to the 2017 AM guidance as the next concrete regulatory signal [S3].
For procurement teams evaluating new chemical material inputs such as photopolymer resins or bio-ink precursors, the next trackable node is the supplier's FDA Drug Master File or Device Master File reference, plus ISO 13485 certification of the powder or resin producer rather than the printer OEM alone [S1][S3]. The same magnetic material and finishing material supply-chain logic applies to surface-treatment and passivation chemistry used post-build, since these directly feed the biocompatibility dossier [S4][S8]. Readers comparing adjacent process routes can also weigh gravity die casting machine selection for energy equipment when justifying why metal AM was chosen over conventional casting for a specific part.